已收盤 02-06 16:00:00 美东时间
+2.380
+2.92%
Adhishthana.com analyses Inhibrx's sharp rally after trial results, highlighting a timing mismatch in the cycle and risks investors should watch.
2025-12-24 20:34
Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology today announced an update on the INBRX-106 Phase 2/3
2025-12-17 06:03
Inhibrx Biosciences, Inc. ( ($INBX) ) has released its Q3 earnings. Here is a b...
2025-11-25 11:57
Companies Reporting Before The Bell • Inhibrx Biosciences (NASDAQ:INBX) is expe...
2025-11-14 19:11
RNA周内大涨42.1%,获诺华120亿美元收购;阿根廷概念股全线飙升,SUPV涨84.5%、END涨71.9%>>
2025-11-01 10:35
【财华社讯】创胜集团-B(06628.HK)公布,合作伙伴Inhibrx Biosciences, Inc.(纳斯达克代码:INBX)公布了注册性临床研究Ch...
2025-10-31 09:57
Wellgistics Health涨185.4%;INHIBRX涨102.0%;Genenta Science S.p.A.涨92.0%
2025-10-25 16:28
Inhibrx Biosciences shares surged nearly 76% in after-hours trading Thursday after the company reported positive Phase 2 trial results for its cancer drug Ozekibart.
2025-10-24 15:05
10月22日,赛诺菲宣布其研发的efdoralprin alfa(SAR447537,前称INBRX-101)在全球ElevAATe II期研究中取得了积极结果...
2025-10-23 17:07
Gainers Ventyx Biosciences (NASDAQ:VTYX) shares rose 51.0% to $5.83 during Wedn...
2025-10-23 05:06